Bafna Pharmaceuticals Ltd. | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 390.6M
Gross Profit 124.8M 31.94%
Operating Income 29.0M 7.42%
Net Income 13.1M 3.36%

Balance Sheet Metrics

Total Assets 1.5B
Total Liabilities 682.7M
Shareholders Equity 848.1M
Debt to Equity 0.81

Cash Flow Metrics

Revenue & Profitability Trend

Bafna Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i1.5B1.5B1.2B851.4M712.2M
Cost of Goods Sold i1.0B1.1B765.9M512.8M454.6M
Gross Profit i428.0M455.6M387.6M338.6M257.6M
Gross Margin % i29.3%29.9%33.6%39.8%36.2%
Operating Expenses
Research & Development i-2.7M7.2M14.7M-
Selling, General & Administrative i-85.3M20.4M25.8M7.8M
Other Operating Expenses i105.9M54.2M38.6M30.2M18.6M
Total Operating Expenses i105.9M142.1M66.3M70.6M26.4M
Operating Income i62.9M74.0M120.7M66.1M61.4M
Operating Margin % i4.3%4.9%10.5%7.8%8.6%
Non-Operating Items
Interest Income i-1.3M445.0K336.0K395.0K
Interest Expense i27.3M19.4M18.0M5.2M886.0K
Other Non-Operating Income-----
Pre-tax Income i41.5M73.5M116.2M52.2M58.3M
Income Tax i002.8M00
Effective Tax Rate % i0.0%0.0%2.4%0.0%0.0%
Net Income i41.5M73.5M113.4M52.2M58.3M
Net Margin % i2.8%4.8%9.8%6.1%8.2%
Key Metrics
EBITDA i139.2M142.9M187.0M133.6M103.9M
EPS (Basic) i₹1.76₹3.11₹4.79₹2.21₹2.46
EPS (Diluted) i₹1.76₹3.11₹4.79₹2.21₹2.46
Basic Shares Outstanding i2359375023656000236560002365600023685772
Diluted Shares Outstanding i2359375023656000236560002365600023685772

Income Statement Trend

Bafna Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i34.3M14.0M78.1M194.0K7.5M
Short-term Investments i-7.0M---
Accounts Receivable i401.7M453.9M411.5M147.8M95.6M
Inventory i280.9M296.4M222.2M202.8M154.4M
Other Current Assets127.1M166.1M156.0M161.7M-1.0K
Total Current Assets i861.8M944.7M873.1M508.8M496.7M
Non-Current Assets
Property, Plant & Equipment i587.8M148.5M141.3M131.1M393.1M
Goodwill i017.7M15.0M00
Intangible Assets i-17.7M15.0M--
Long-term Investments-----
Other Non-Current Assets--2.0K-3.0K-2.0K-2.0K
Total Non-Current Assets i669.0M532.1M422.7M392.6M368.0M
Total Assets i1.5B1.5B1.3B901.4M864.7M
Liabilities
Current Liabilities
Accounts Payable i309.5M354.2M284.6M124.0M106.9M
Short-term Debt i141.7M136.4M144.9M57.4M105.0M
Current Portion of Long-term Debt-----
Other Current Liabilities26.0M18.3M21.2M21.5M21.5M
Total Current Liabilities i518.5M540.8M464.8M220.1M243.1M
Non-Current Liabilities
Long-term Debt i140.3M107.5M84.3M53.2M25.0M
Deferred Tax Liabilities i---00
Other Non-Current Liabilities-3.0K-10.7M1.0K
Total Non-Current Liabilities i164.2M127.6M96.5M61.7M53.9M
Total Liabilities i682.7M668.4M561.3M281.8M296.9M
Equity
Common Stock i236.6M236.6M236.6M236.6M236.6M
Retained Earnings i--471.0M-544.8M-659.7M-711.7M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i848.1M808.4M734.5M619.6M567.7M
Key Metrics
Total Debt i282.0M243.9M229.2M110.6M130.0M
Working Capital i343.3M403.9M408.4M288.7M253.6M

Balance Sheet Composition

Bafna Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i41.5M73.5M116.2M51.9M58.3M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i120.1M-126.8M-297.0M-145.7M-214.0M
Operating Cash Flow i207.7M-32.7M-164.1M-93.7M-162.4M
Investing Activities
Capital Expenditures i-218.0M-154.1M-65.2M-75.4M-60.9M
Acquisitions i-----
Investment Purchases i-5.0K----
Investment Sales i-----
Investing Cash Flow i-213.0M-149.1M-60.2M-65.6M-53.8M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i----88.2M98.7M
Free Cash Flow i2.8M-63.6M-32.7M21.9M-197.0M
Net Change in Cash i-5.4M-181.8M-224.3M-247.5M-117.5M

Cash Flow Trend

Bafna Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 28.29
Price to Book 2.78
Price to Sales 1.60
PEG Ratio -0.05

Profitability Ratios

Profit Margin 5.62%
Operating Margin 10.68%
Return on Equity 4.90%
Return on Assets 2.71%

Financial Health

Current Ratio 1.66
Debt to Equity 33.25
Beta 0.19

Per Share Data

EPS (TTM) ₹3.50
Book Value per Share ₹35.58
Revenue per Share ₹62.14

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
bafnaph2.4B28.292.784.90%5.62%33.25
Sun Pharmaceutical 3.9T37.745.4315.08%19.29%3.26
Divi's Laboratories 1.6T70.8710.9114.64%23.89%0.03
Sun Pharma Advanced 47.8B-13.92-21.95157.88%-53.22%-1.24
Aarti Drugs 43.0B22.813.1412.28%7.80%44.92
Sequent Scientific 44.3B153.956.282.84%1.85%62.47

Financial data is updated regularly. All figures are in the company's reporting currency.